Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013;35(5):352-7.
doi: 10.5581/1516-8484.20130113.

Phase I clinical trial of cell therapy in patients with advanced chronic obstructive pulmonary disease: follow-up of up to 3 years

Talita Stessuk  1 , Milton Artur Ruiz, Oswaldo Tadeu Greco, Aldemir Bilaqui, Maria José de Oliveira Ribeiro-Paes, João Tadeu Ribeiro-Paes
Affiliations

Phase I clinical trial of cell therapy in patients with advanced chronic obstructive pulmonary disease: follow-up of up to 3 years

Talita Stessuk et al. Rev Bras Hematol Hemoter. 2013.

Abstract

Background: Chronic obstructive pulmonary disease is a major inflammatory disease of the airways and an enormous therapeutic challenge. Within the spectrum of chronic obstructive pulmonary disease, pulmonary emphysema is characterized by the destruction of the alveolar walls with an increase in the air spaces distal to the terminal bronchioles but without significant pulmonary fibrosis. Therapeutic options are limited and palliative since they are unable to promote morphological and functional regeneration of the alveolar tissue. In this context, new therapeutic approaches, such as cell therapy with adult stem cells, are being evaluated.

Objective: This article aims to describe the follow-up of up to 3 years after the beginning of a phase I clinical trial and discuss the spirometry parameters achieved by patients with advanced pulmonary emphysema treated with bone marrow mononuclear cells.

Methods: Four patients with advanced pulmonary emphysema were submitted to autologous infusion of bone marrow mononuclear cells. Follow-ups were performed by spirometry up to 3 years after the procedure.

Results: The results showed that autologous cell therapy in patients having chronic obstructive pulmonary disease is a safe procedure and free of adverse effects. There was an improvement in laboratory parameters (spirometry) and a slowing down in the process of pathological degeneration. Also, patients reported improvements in the clinical condition and quality of life.

Conclusions: Despite being in the initial stage and in spite of the small sample, the results of the clinical protocol of cell therapy in advanced pulmonary emphysema as proposed in this study, open new therapeutic perspectives in chronic obstructive pulmonary disease. It is worth emphasizing that this study corresponds to the first study in the literature that reports a change in the natural history of pulmonary emphysema after the use of cell therapy with a pool of bone marrow mononuclear cells.

Keywords: Cell transplantation; Clinical trial, phase I; Pulmonary disease, chronic obstructive; Pulmonary emphysema; Spirometry; Stem cells.

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest disclosure: The authors declare no competing financial interest

Figures

Figure 1
Figure 1
Spirometric values achieved by Patient 2; A) Forced expiratory volume in 1 second (FEV1), Forced vital capacity (FVC) and vital capacity (VC); B) Percentages predicted for FEV1, FVC and the FEV1/FVC ratio; pre- and post-bronchodilator values
Figure 2
Figure 2
Spirometric values achieved by Patient 3; A) Forced expiratory volume in 1 second (FEV1), Forced vital capacity (FVC) and vital capacity (VC); B) Percentages predicted for FEV1, FVC and the FEV1/FVC ratio; pre- and post-bronchodilator values
Figure 3
Figure 3
Spirometric values achieved by Patient 4; A) Forced expiratory volume in 1 second (FEV1), Forced vital capacity (FVC) and vital capacity (VC); B) Percentages predicted for FEV1, FVC and the FEV1/FVC ratio; pre- and post-bronchodilator values
See this image and copyright information in PMC

References

    1. Global Initiative for Chronic Obstructive Lung Disease GOLD Global Strategy for Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease [Internet] [cited 2013 June 02]. Available from: http://www.goldcopd.org/uploads/users/files/GOLD_Report_2013_Feb20.pdf.
    1. II Consenso Brasileiro sobre Doença Pulmonar Obstrutiva Crônica (DPOC) J Bras Pneumol. 2004;30(Supl 5):S1–S42.
    1. Mannino DM. The natural history of chronic obstructive pulmonary disease. Pneumonol Alergol Pol. 2011;79(2):139–143. - PubMed
    1. Faria CA de, las Heras Kozma R de, Stessuk T, Ribeiro-Paes JT. Experimental basis and new insights for cell therapy in Chronic Obstructive Pulmonary Disease. Stem Cell Rev. 2012;8(4):1236–1244. - PubMed
    1. Ribeiro-Paes JT, Stessuk T, Heras Kozma R de. Cell therapy in Chronic Obstructive Pulmonary Disease: state of the art and perspectives. In: Kian-Chung, editor. Chronic Obstructive Pulmonary Disease - Current Concepts and Practice [Internet] Singapore: Intech; 2012. [cited 2012 mar 2]. Available from: http://www.intechopen.com/books/chronic-obstructive-pulmonary-disease-cu....

LinkOut - more resources